Denali Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Collaboration revenue: | ||
| Collaboration revenue from customers(1) | $— | $35,141 |
| Total collaboration revenue | — | 35,141 |
| Operating expenses: | ||
| Research and development(2) | 107,016 | 128,816 |
| General and administrative | 25,236 | 27,140 |
| Total operating expenses | 132,252 | 155,956 |
| Gain from divestiture of small molecule programs | 14,537 | — |
| Loss from operations | (117,715) | (120,815) |
| Interest and other income, net | 15,913 | 11,034 |
| Net loss | (101,802) | (109,781) |
| Other comprehensive income (loss): | ||
| Net unrealized gain (loss) on marketable securities, net of tax | (1,939) | 4,369 |
| Comprehensive loss | $(103,741) | $(105,412) |
| Net loss per share, basic and diluted | $(0.68) | $(0.80) |
| Weighted average number of shares outstanding, basic and diluted | 149,404,188 | 136,524,528 |
(1)Includes related-party collaboration revenue from customers of $0.1 million for the three months ended March 31, 2023.
(2)Includes expenses for cost sharing payments due to a related party of $4.2 million for the three months ended March 31, 2023.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.